Aranesp Settlement Results in $762M Payment by Amgen

Amgen has agreed to pay $762 million to settle a whistleblower lawsuit and criminal charges this week, which allege that the drug maker illegally promoted their anemia medications Aranesp and Epogen. 

The settlement and plea agreement includes a $150 million criminal penalty, with the remainder of the money used to settle 10 different lawsuits.

The U.S. attorney’s office in charge of the case secured the deal in federal court in Brooklyn, New York on Tuesday. The deal includes a $612 million civil settlement, $136 million in criminal fines and a $14 million criminal forfeiture payment.

The company will also enter into a five-year corporate integrity agreement requiring that the company will meet federal regulations or executives and members of its board will be held directly responsible by the government.

Amgen Allegedly Offered Illegal Deals to Doctors

Aranesp (darbepoetin alfa) and Epogen (Epoetin alfa) are prescribed to patients with kidney disease, anemia, HIV and cancer to stimulate bones to increase the production of red blood cells. They are also prescribed to patients preparing to undergo major non-heart surgery to reduce the number of transfusions such patients must receive. In 2008, Aranesp sales were $3.1 billion.

According to a Washington Post report in July, Amgen allegedly encouraged doctors to use the drugs by overfilling vials by as much as 25 percent, and offered discounts to doctors who used the drugs in large volume. This allowed doctors to take advantage of what is known as the “spread,” the difference between the price they paid for the drugs and the price they charged patients.

Lobbyists were also employed to help, getting Congress and Medicare officials to sign off on a pricing structure that allowed doctors and hospitals to be reimbursed for more than they actually paid for the drugs.

The Medicare Payment Advisory Commission estimates that the overpayments reached as high as 30%. Some doctors made as much as $300,000 a year off of the drugs alone, while helping Amgen generate huge profits.

This week’s settlement means that the plaintiffs who brought the 10 whistleblower lawsuits will receive a percentage of the civil settlement money collected by the government. Under the qui tam provision of the False Claims Act, whistleblowers who report a false claim against the government may be entitled to receive a portion of any money that the government recovers. In return, the whistleblower must be the first to bring the case to the government’s attention, and must not publicize the claim until the Justice Department decides to prosecute the claim.

Image Credit: |

1 Comments

  • DanaMarch 20, 2019 at 5:19 am

    My daughter has experienced many Problems with Fresenius dialysis clinic. Most seem very unethical and Endangering her life. Refuse to change dialyzers when Allergic Forced cutting of treatment times Unsanitary methods Flooding of clinics standing water Recording false statements in to Medical records We have found the personnel in Professional

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.